ALSO NOTED: Big CEO turnover at Big Pharma; New company takes on RNAi field; Shire hunts for buyouts; and much more...

> Turnover at the top of Big Pharma has been running at an unprecedented pace. And now, with fresh faces at the helm at nine of the world's top 12 pharma companies, there's a new generation running things. Report

> According to The In Vivo Blog, a new company is taking on the hot field of RNAi. Dicerna Pharmaceuticals is expected to announce a $13 million first round of funding led by Oxford Biosciences. Post

> Fresh off its best quarterly results ever, Shire says it's still in the market for smaller companies to buy. Report

And Finally... Case Western Reserve University researchers have bred a line of "mighty mice" that can run five to six kilometers at a speed of 20 meters per minute on a treadmill for up to six hours before stopping. Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.